Predictive and prognostic angiogenic markers in a gynecologic oncology group phase II trial of bevacizumab in recurrent and persistent ovarian or peritoneal cancer.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples